Should the ASCO/ASH guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated?

Keyphrases

• In Cancer 100%
• Cancer-related Anemia 100%
• Cancer Chemotherapy 100%
• Intravenous Iron 100%
• Erythropoiesis-stimulating Agents 60%
• Cancer-related 30%
• Hemoglobin 20%
• Adverse Events 20%
• Clinically Significant 10%
• Response Rate 10%
• Absence of Evidence 10%
• Oncologists 10%
• Response Predictors 10%
• Hemoglobin Level 10%
• Financial Resources 10%
• Cancer Treatment 10%
• Serious Adverse Events 10%
• Safety Concerns 10%
• Risk-benefit Ratio 10%
• Payers 10%
• Standard of Care 10%
• Same-day 10%
• Misinterpretation 10%
• Time Targets 10%
• Self-limiting 10%
• Premedication 10%
• Antihistamines 10%
• Anaphylaxis 10%
• Response Magnitude 10%
• Hemodynamically Significant 10%
• Serum Hepcidin 10%
• Hepcidin Levels 10%
• Favorable Risk 10%
• Hemoglobin A 10%
• Vasopressors 10%
• Infusion Reaction 10%
• Parenteral Iron 10%
• Haemoglobin Target 10%
• Clinical Adoption 10%
• Iron Products 10%

Medicine and Dentistry

• Malignant Neoplasm 100%
• Hematinic 100%
• Chemotherapy Induced Anemia 100%
• Adverse Event 50%
• Prospective Study 16%
• Symptom 16%
• Infusion 16%
• Cancer Treatment 16%
• Risk-Benefit Ratio 16%
• Hypertensive Factor 16%
• Premedication 16%
• Histamine Antagonist 16%
• Anaphylaxis 16%
• Hepcidin 16%
• Oncologist 16%
• Iron Product 16%